Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation

Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation

Abstract Background Osimertinib (AZD9291) is a third‐generation EGFR‐tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR‐mutant non‐small cell lung cancer (NSCLC). However, acquired resistance to osim...

Full description

Bibliographic Details
Main Authors: Daisuke Hayakawa, Fumiyuki Takahashi, Yoichiro Mitsuishi, Ken Tajima, Moulid Hidayat, Wira Winardi, Hiroaki Ihara, Koichiro Kanamori, Naohisa Matsumoto, Tetsuhiko Asao, Ryo Ko, Takehito Shukuya, Kazuya Takamochi, Takuo Hayashi, Yoshiyuki Suehara, Ikuko Takeda Nakamura, Toshihide Ueno, Shinji Kohsaka, Hiroyuki Mano, Kazuhisa Takahashi
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Thoracic Cancer
Subjects:
EGFR‐TKI
IGF1R
NSCLC
osimertinib
resistance
Online Access:https://doi.org/10.1111/1759-7714.13255

Internet

https://doi.org/10.1111/1759-7714.13255

Similar Items